Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in Small Bowel Crohn's Disease
NCT03046056Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of filgotinib in Crohn's disease (3 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants Who Achieved Clinical Remission at 24 weeks. Started Apr 2017; status: completed.
02
Drugs
filgotinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03046056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03046056.